Literature DB >> 33075414

Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series.

Karolina L Kerkemeyer1, Nekma Meah2, Rodney D Sinclair2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33075414     DOI： 10.1016/j.jaad.2020.10.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.

Authors:  Marcia A Friedman; Brian Le; Janelle Stevens; Julianna Desmarais; Daniel Seifer; Kimberly Ogle; Dongseok Choi; Christina A Harrington; Peter Jackson; James T Rosenbaum
Journal:  Lung       Date:  2021-04-07       Impact factor: 2.584

2.  The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells.

Authors:  Michael A Paley; Brandi J Baker; S Richard Dunham; Nicole Linskey; Claudia Cantoni; Kenneth Lee; Lynn M Hassman; Jennifer Laurent; Elisha D O Roberson; David B Clifford; Wayne M Yokoyama
Journal:  J Neuroimmunol       Date:  2022-04-01       Impact factor: 3.221

3.  Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Authors:  William Damsky; Alice Wang; Daniel J Kim; Bryan D Young; Katelyn Singh; Michael J Murphy; Joseph Daccache; Abigale Clark; Ruveyda Ayasun; Changwan Ryu; Meaghan K McGeary; Ian D Odell; Ramesh Fazzone-Chettiar; Darko Pucar; Robert Homer; Mridu Gulati; Edward J Miller; Marcus Bosenberg; Richard A Flavell; Brett King
Journal:  Nat Commun       Date:  2022-06-06       Impact factor: 17.694

4.  Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis.

Authors:  Ronan Talty; William Damsky; Brett King
Journal:  JAAD Case Rep       Date:  2021-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.